IL3 and myelodysplastic syndrome: To study SL-401 as a possible treatment for diagnosis of AML and high-risk MDS. To determine the safest, highest dose of study drug, SL-401, in combination with azacitidine that can be given to patients with AML or high-risk MDS. To study the side effects and best dose of DT(388)IL3 fusion protein SL-401 when given together with azacitidine in treating patients with myelodysplastic syndrome or acute myeloid leukemia that is untreated, has come back, or does not respond to treatment.